Program
roginolisib
Also written as “IOA-244” and “Roginolisib”.
Its studies are mostly in Lymphoma, Non-Hodgkin · Primary Myelofibrosis · Uveal Melanoma · Carcinoma, Non-Small-Cell Lung, led by iOnctura.
Furthest: phase 2, since Nov 18, 20244 company-led studies, 4 open or runningNext primary completion: Jan 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| iOnctura | 44 open or running | phase 2since Nov 18, 2024 | Mar 11, 2020 | Jan 2027phase 2 · NCT06879717 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2020First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT04328844 · 210 enrolled · Italy, United Kingdom
- Nov 18, 2024Phase 2 study in Uveal MelanomaNCT06717126 · 85 enrolled · Italy, Spain, United Kingdom
- Feb 26, 2025Phase 2 study in Primary MyelofibrosisNCT06887803 · 26 planned · Italy, Spain, United Kingdom
- Mar 5, 2025Phase 2 study in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06879717 · 45 enrolled · Belgium, Italy, Spain
Ahead
- Jan 2027Primary completion: phase 2 study in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06879717
- Dec 2027Primary completion: phase 2 study in Uveal MelanomaNCT06717126
- Mar 2028Primary completion: phase 2 study in Primary MyelofibrosisNCT06887803
TargetBeta
PIK3CD →read by rule
“A Phase 1/2, Open Label, Study of Roginolisib (IOA-244), an Orally Bioavailable, Selective PI3Kδ Inhibitor in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) in Combination With Venetoclax and Rituximab”study text, by rule · the study
Other programs on PIK3CD
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| idelalisibrule | Gilead Sciences | phase 4 | 28 |
| duvelisibrule | SecuraBio | phase 3 | 26 |
| leniolisibrule | Pharming Group | phase 3 | 9 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06879717Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · Belgium, Italy, Spain | 2 | Active, not recruiting | Jan 2027 | 45 |
| NCT06887803Primary Myelofibrosis · Italy, Spain, United Kingdom | 2 | Recruiting | Mar 2028 | 26 |
| NCT06717126Uveal Melanoma · Italy, Spain, United Kingdom | 2 | Active, not recruiting | Dec 2027 | 85 |
| NCT04328844Lymphoma, Non-Hodgkin · Italy, United Kingdom | 1 | Active, not recruiting | Dec 13, 2023 | 210 |
How it is read
Names in the registry
- “roginolisib”, 2 entries
- “IOA-244”, 1 entry
- “Roginolisib”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 1 study
- Primary Myelofibrosis, 1 study
- Uveal Melanoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.